Presidio, Boehringer to commence Phase IIa direct-acting antiviral combination treatment trial
The all-oral combination comprises Presidio’s HCV NS5A inhibitor (PPI-668), Boehringer’s HCV protease inhibitor Faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin. The trial
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.